Xcout Intel
Eureka Therapeutics Inc
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Subscribe to see Eureka Therapeutics Inc’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Eureka Therapeutics Inc at a glance
Eureka Therapeutics Inc is a biotechnology company headquartered in United States. Its most recent funding round raised $20M in May 2023. Xcout tracks 1 named person at Eureka Therapeutics Inc, including Alexa Willson (Chief Financial Officer).
Eureka Therapeutics Inc leadership
- Alexa WillsonChief Financial Officer
Eureka Therapeutics Inc funding rounds
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — | |
| SEC Form D filing | $45M | — | |
| — | $60M | 1 named | |
| SEC Form D filing | $20M | — | |
| SEC Form D filing | $40M | — | |
| Series C | $21M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Eureka Therapeutics Inc competitors
A few of Eureka Therapeutics Inc's closest competitors — see the full list of competitors and alternatives →
Excalipoint Therapeutics is a clinical-stage biotechnology company headquartered in Shanghai, China. The firm is dedicated to developing next-generation T-cell engager (TCE) therapies and unlocking the therapeutic potential of T-cell based treatments.
Eutilex is a biopharmaceutical company that develops innovative immunotherapeutics, including antibody treatments, T-cell therapies, and CAR-T cell therapies. The company focuses on creating treatments for incurable and intractable diseases through continuous research and development.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Revolution Medicines is a clinical-stage oncology company that develops novel targeted therapies to outsmart cancer. The company focuses on discovering and advancing therapeutic pipelines for patients with difficult-to-treat tumors.
CytoImmune Therapeutics is a clinical-stage biotechnology company headquartered in Duarte, California, focused on developing novel cell therapies for cancer treatment.
Get Eureka Therapeutics Inc's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Eureka Therapeutics Inc in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 7 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access